Methimazole is a thioamide immunomodulatory anti-thyroid compound that is clinically used to treat hyperthyroidism and Graves’ disease. Methimazole is an irreversible inhibitor of thyroid peroxidase; it decreases levels of CXCL10 and downregulates expression of IFNγ receptors.
| Cas No. | 60-56-0 |
|---|---|
| Purity | ≥98% |
| Formula | C4H6N2S |
| Formula Wt. | 114.17 |
| Chemical Name | 1,3-Dihydro-1-methyl-2H-imidazole-2-thione |
| IUPAC Name | 3-methyl-1H-imidazole-2-thione |
| Synonym | Basolan; Favistan; Frentirox; Mercazole; Tapazole; Thycapsol; Strumazol |
| Melting Point | 146-148°C |
| Solubility | Soluble in water (200 mg/mL), ethanol (200 mg/mL), or chloroform. Slightly soluble in ether or benzene. |
| Appearance | White Crystal Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | M1976 Info Sheet PDF |
|---|
Rivkees SA. Pediatric Graves' disease: management in the post-propylthiouracil Era. Int J Pediatr Endocrinol. 2014;2014(1):10. PMID: 25089127.
Manna D, Roy G, Mugesh G. Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action. Acc Chem Res. 2013 Nov 19;46(11):2706-15. PMID: 23883148.
Crescioli C, Cosmi L, Borgogni E, et al. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol. 2007 Oct;195(1):145-55. PMID: 17911406.
